| 28.98 Data as of May 24 |  +0.92 / +3.28%Today’s Change | 9.94 Today|||52-Week Range 29.07 | +58.79% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Biotechnology | MARKET CAP $1.7B |
Company Description
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company, which develops novel therapeutics based on RNA interference. It is leading the translation of RNAi as a new class of innovative medicines with a core focus on RNAi therapeutics for the treatment of genetically defined diseases, including ALN-TTR for the treatment of transthyretin-mediated amyloidosis, ALN-PCS for the treatment of severe hypercholesterolemia, ALN-HPN for the treatment of refractory anemia, ALN-APC for the treatment of hemophilia, and ALN-TMP for the treatment of hemoglobinopathies. Alnylam Pharmaceuticals was founded by John Kennedy Clarke, Paul R. Schimmel and Phillip A. Sharp on June 14, 2002 and is headquartered in Cambridge, MA.
Employees
Shareholders
| Mutual fund holders | 42.70% |
| Other institutional | 42.50% |
| Individual stakeholders | 18.33% |
Top Executives
| John K. Clarke, MBA | Chairman |
| Barry E. Greene | President & Chief Operating Officer |
| John M. Maraganore, PhD | Chief Executive Officer & Director |
| Michael P. Mason, MBA, CPA | Treasurer & Vice President-Finance |
| Jared Gollob, MD | Vice President-Clinical Research |
.
